Compare Novo Nordisk A/S (NVO) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.58. The key difference: Novo Nordisk A/S pays a 3.63% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NVO | YMAG | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $71.70 | $15.98 |
52-Week Low | $35.29 | $11.00 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
YMAG trades at $11.63, up 0.17% with a bearish technical signal from moving averages. The ETF provides weekly distributions, recently ranging from $0.07 to $0.40 per share, targeting income through covered calls on Magnificent Seven stocks. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights distribution announcements and strategy discussions amid mixed sentiment regarding its performance versus peers.
Outlook hinges on volatility monetization via options, offering high yield but facing NAV decay risks. Investment appeal lies in income generation during range-bound markets, though underperformance in rising equity environments and high expenses pose challenges. Risks include dependency on underlying stock volatility and competitive ETF pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
